Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio Companies

Core Viewpoint - Scilex Holding Company has secured a $100 million financing commitment from Perigrove LLC and Graf Holdings to enhance its capital position and support its growth in non-opioid pain management products, aiming for revenues exceeding $1 billion in the next 4-5 years [19][20]. Financing Details - The financing consists of a 5-year term loan with royalty-based payments, intended to repay approximately $85 million of existing senior secured debt to Oramed Pharmaceuticals Inc. and allocate around $15 million for general corporate purposes [19][20]. - Upon receipt of the commitment funds, Scilex will issue a warrant to purchase up to 32,500,000 shares of its common stock at an exercise price of $1.20 [1]. Product Pipeline - Scilex is developing three product candidates: - SP-102, a viscous gel formulation for epidural injections to treat lumbosacral radicular pain, which has completed Phase 3 studies and received Fast Track status from the FDA [4]. - SP-103, a next-generation lidocaine topical system for chronic neck pain, which has recently completed a Phase 2 trial [4]. - SP-104, a low-dose naltrexone hydrochloride for fibromyalgia, with Phase 1 trials completed in Q2 2022 [4]. Company Overview - Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, with a commitment to improving patient outcomes [10][11]. - The company's commercial products include ZTlido®, ELYXYB®, and Gloperba®, with Gloperba expected to launch in the first half of 2024 [10][19]. Strategic Positioning - The financing commitment is expected to enhance Scilex's commercial position and reduce reliance on future capital raising activities, allowing for reinvestment in its commercial products [20][21].